Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
1171 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Liver Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cancer - Pipeline Review, H2 2016, provides an overview of the Liver Cancer (Oncology) pipeline landscape. Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Liver Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 76, 52, 8, 121 and 19 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 15, 8, 1, 30 and 3 molecules, respectively. Liver Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Liver Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Liver Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Liver Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Liver Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Liver Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 10 Liver Cancer Overview 11 Therapeutics Development 12 Liver Cancer - Therapeutics under Development by Companies 14 Liver Cancer - Therapeutics under Investigation by Universities/Institutes 29 Liver Cancer - Pipeline Products Glance 32 Liver Cancer - Products under Development by Companies 35 Liver Cancer - Products under Investigation by Universities/Institutes 56 Liver Cancer - Companies Involved in Therapeutics Development 60 Liver Cancer - Therapeutics Assessment 245 Drug Profiles 277 Liver Cancer - Dormant Projects 1096 Liver Cancer - Discontinued Products 1116 Liver Cancer - Product Development Milestones 1120 Appendix 1133
List of Tables
Number of Products under Development for Liver Cancer, H2 2016 49 Number of Products under Development for Liver Cancer - Comparative Analysis, H2 2016 50 Number of Products under Development by Companies, H2 2016 51 Number of Products under Development by Companies, H2 2016 (Contd..1) 52 Number of Products under Development by Companies, H2 2016 (Contd..2) 53 Number of Products under Development by Companies, H2 2016 (Contd..3) 54 Number of Products under Development by Companies, H2 2016 (Contd..4) 55 Number of Products under Development by Companies, H2 2016 (Contd..5) 56 Number of Products under Development by Companies, H2 2016 (Contd..6) 57 Number of Products under Development by Companies, H2 2016 (Contd..7) 58 Number of Products under Development by Companies, H2 2016 (Contd..8) 59 Number of Products under Development by Companies, H2 2016 (Contd..9) 60 Number of Products under Development by Companies, H2 2016 (Contd..10) 61 Number of Products under Development by Companies, H2 2016 (Contd..11) 62 Number of Products under Development by Companies, H2 2016 (Contd..12) 63 Number of Products under Development by Companies, H2 2016 (Contd..13) 64 Number of Products under Development by Companies, H2 2016 (Contd..14) 65 Number of Products under Investigation by Universities/Institutes, H2 2016 66 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 67 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 68 Comparative Analysis by Late Stage Development, H2 2016 69 Comparative Analysis by Clinical Stage Development, H2 2016 70 Comparative Analysis by Early Stage Development, H2 2016 71 Products under Development by Companies, H2 2016 72 Products under Development by Companies, H2 2016 (Contd..1) 73 Products under Development by Companies, H2 2016 (Contd..2) 74 Products under Development by Companies, H2 2016 (Contd..3) 75 Products under Development by Companies, H2 2016 (Contd..4) 76 Products under Development by Companies, H2 2016 (Contd..5) 77 Products under Development by Companies, H2 2016 (Contd..6) 78 Products under Development by Companies, H2 2016 (Contd..7) 79 Products under Development by Companies, H2 2016 (Contd..8) 80 Products under Development by Companies, H2 2016 (Contd..9) 81 Products under Development by Companies, H2 2016 (Contd..10) 82 Products under Development by Companies, H2 2016 (Contd..11) 83 Products under Development by Companies, H2 2016 (Contd..12) 84 Products under Development by Companies, H2 2016 (Contd..13) 85 Products under Development by Companies, H2 2016 (Contd..14) 86 Products under Development by Companies, H2 2016 (Contd..15) 87 Products under Development by Companies, H2 2016 (Contd..16) 88 Products under Development by Companies, H2 2016 (Contd..17) 89 Products under Development by Companies, H2 2016 (Contd..18) 90 Products under Development by Companies, H2 2016 (Contd..19) 91 Products under Development by Companies, H2 2016 (Contd..20) 92 Products under Investigation by Universities/Institutes, H2 2016 93 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 94 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 95 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 96 Liver Cancer - Pipeline by 4SC AG, H2 2016 97 Liver Cancer - Pipeline by AB Science SA, H2 2016 98 Liver Cancer - Pipeline by Acceleron Pharma Inc, H2 2016 99 Liver Cancer - Pipeline by ACROVIS Pharma AG, H2 2016 100 Liver Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 101 Liver Cancer - Pipeline by Aduro BioTech Inc, H2 2016 102 Liver Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 103 Liver Cancer - Pipeline by Alfact Innovation, H2 2016 104 Liver Cancer - Pipeline by Alissa Pharma, H2 2016 105 Liver Cancer - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 106 Liver Cancer - Pipeline by American Gene Technologies International Inc, H2 2016 107 Liver Cancer - Pipeline by Amgen Inc, H2 2016 108 Liver Cancer - Pipeline by AndroScience Corp, H2 2016 109 Liver Cancer - Pipeline by APAvadis Biotechnologies Srl, H2 2016 110 Liver Cancer - Pipeline by ArQule Inc, H2 2016 111 Liver Cancer - Pipeline by Array BioPharma Inc, H2 2016 112 Liver Cancer - Pipeline by Astellas Pharma Inc, H2 2016 113 Liver Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 114 Liver Cancer - Pipeline by AstraZeneca Plc, H2 2016 115 Liver Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 116 Liver Cancer - Pipeline by Bayer AG, H2 2016 117 Liver Cancer - Pipeline by BeiGene Ltd, H2 2016 118 Liver Cancer - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016 119 Liver Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016 120 Liver Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 121 Liver Cancer - Pipeline by BioCancell Ltd, H2 2016 122 Liver Cancer - Pipeline by Biogazelle NV, H2 2016 123 Liver Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2016 124 Liver Cancer - Pipeline by Bioneer Corp, H2 2016 125 Liver Cancer - Pipeline by BioStar Pharmaceuticals Inc, H2 2016 126 Liver Cancer - Pipeline by BLR Bio LLC, H2 2016 127 Liver Cancer - Pipeline by Blueprint Medicines Corp, H2 2016 128 Liver Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 129 Liver Cancer - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 130 Liver Cancer - Pipeline by Boston Biomedical Inc, H2 2016 131 Liver Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 132 Liver Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016 133 Liver Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016 134 Liver Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2016 135 Liver Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2016 136 Liver Cancer - Pipeline by Celgene Corp, H2 2016 137 Liver Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 138 Liver Cancer - Pipeline by Celprogen Inc, H2 2016 139 Liver Cancer - Pipeline by Celsion Corp, H2 2016 140 Liver Cancer - Pipeline by China Medical System Holdings Ltd, H2 2016 141 Liver Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 142 Liver Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016 143 Liver Cancer - Pipeline by Chroma Therapeutics Ltd, H2 2016 144 Liver Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 145 Liver Cancer - Pipeline by CohBar Inc, H2 2016 146 Liver Cancer - Pipeline by CZ BioMed Corp, H2 2016 147 Liver Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 148 Liver Cancer - Pipeline by Delcath Systems Inc, H2 2016 149 Liver Cancer - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 150 Liver Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 151 Liver Cancer - Pipeline by Eisai Co Ltd, H2 2016 152 Liver Cancer - Pipeline by Eli Lilly and Company, H2 2016 153 Liver Cancer - Pipeline by Endocyte Inc, H2 2016 154 Liver Cancer - Pipeline by Epeius Biotechnologies Corp, H2 2016 155 Liver Cancer - Pipeline by eTheRNA Immunotherapies NV, H2 2016 156 Liver Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016 157 Liver Cancer - Pipeline by Exelixis Inc, H2 2016 158 Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 159 Liver Cancer - Pipeline by Faron Pharmaceuticals Oy, H2 2016 160 Liver Cancer - Pipeline by Formosa Laboratories Inc, H2 2016 161 Liver Cancer - Pipeline by Galaxy Biotech LLC, H2 2016 162 Liver Cancer - Pipeline by Genelux Corp, H2 2016 163 Liver Cancer - Pipeline by Genoscience Pharma, H2 2016 164 Liver Cancer - Pipeline by Genosco Inc, H2 2016 165 Liver Cancer - Pipeline by Gilead Sciences Inc, H2 2016 166 Liver Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 167 Liver Cancer - Pipeline by Golden Biotechnology Corp, H2 2016 168 Liver Cancer - Pipeline by Green Cross Cell Corp, H2 2016 169 Liver Cancer - Pipeline by Green Cross Corp, H2 2016 170 Liver Cancer - Pipeline by H3 Biomedicine Inc, H2 2016 171 Liver Cancer - Pipeline by HanAll Biopharma Co Ltd, H2 2016 172 Liver Cancer - Pipeline by HEC Pharm Co Ltd, H2 2016 173 Liver Cancer - Pipeline by HitGen LTD, H2 2016 174 Liver Cancer - Pipeline by Horizon Pharma Plc, H2 2016 175 Liver Cancer - Pipeline by Immune Therapeutics Inc, H2 2016 176 Liver Cancer - Pipeline by Immunicum AB, H2 2016 177 Liver Cancer - Pipeline by Immunitor Inc, H2 2016 178 Liver Cancer - Pipeline by Immunomedics Inc, H2 2016 179 Liver Cancer - Pipeline by Immunophotonics Inc, H2 2016 180 Liver Cancer - Pipeline by Immunovative Therapies Ltd, H2 2016 181 Liver Cancer - Pipeline by IMPACT Therapeutics Inc, H2 2016 182 Liver Cancer - Pipeline by In-Cell-Art SAS, H2 2016 183 Liver Cancer - Pipeline by Incanthera Ltd, H2 2016 184 Liver Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 185 Liver Cancer - Pipeline by Inspyr Therapeutics Inc, H2 2016 186 Liver Cancer - Pipeline by InteRNA Technologies BV, H2 2016 187 Liver Cancer - Pipeline by Intezyne Technologies Inc, H2 2016 188 Liver Cancer - Pipeline by Jasco Pharmaceuticals LLC, H2 2016 189 Liver Cancer - Pipeline by Jenrin Discovery Inc, H2 2016 190 Liver Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 191 Liver Cancer - Pipeline by Johnson & Johnson, H2 2016 192 Liver Cancer - Pipeline by JW Pharmaceutical Corp, H2 2016 193 Liver Cancer - Pipeline by KAHR medical Ltd, H2 2016 194 Liver Cancer - Pipeline by Karcinolys SAS, H2 2016 195 Liver Cancer - Pipeline by Keystone Nano Inc, H2 2016 196 Liver Cancer - Pipeline by Kite Pharma Inc, H2 2016 197 Liver Cancer - Pipeline by Komipharm International Co Ltd, H2 2016 198 Liver Cancer - Pipeline by Kowa Company Ltd, H2 2016 199 Liver Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016 200 Liver Cancer - Pipeline by Lidds AB, H2 2016 201 Liver Cancer - Pipeline by Ligand Pharmaceuticals Inc, H2 2016 202 Liver Cancer - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 203 Liver Cancer - Pipeline by Lytix Biopharma AS, H2 2016 204 Liver Cancer - Pipeline by MaxCyte Inc, H2 2016 205 Liver Cancer - Pipeline by MedImmune LLC, H2 2016 206 Liver Cancer - Pipeline by Medivation Inc, H2 2016 207 Liver Cancer - Pipeline by Medivir AB, H2 2016 208 Liver Cancer - Pipeline by Merck & Co Inc, H2 2016 209 Liver Cancer - Pipeline by Merck KGaA, H2 2016 210 Liver Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 211 Liver Cancer - Pipeline by Midatech Pharma Plc, H2 2016 212 Liver Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 213 Liver Cancer - Pipeline by Mina Therapeutics Ltd, H2 2016 214 Liver Cancer - Pipeline by Molecular Partners AG, H2 2016 215 Liver Cancer - Pipeline by MultiCell Technologies Inc, H2 2016 216 Liver Cancer - Pipeline by NormOxys Inc, H2 2016 217 Liver Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016 218 Liver Cancer - Pipeline by Novartis AG, H2 2016 219 Liver Cancer - Pipeline by NovaTarg Therapeutics Inc, H2 2016 220 Liver Cancer - Pipeline by Nymox Pharmaceutical Corp, H2 2016 221 Liver Cancer - Pipeline by Omeros Corp, H2 2016 222 Liver Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2016 223 Liver Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016 224 Liver Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 225 Liver Cancer - Pipeline by OncoTherapy Science Inc, H2 2016 226 Liver Cancer - Pipeline by Oneness Biotech Co Ltd, H2 2016 227 Liver Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 228 Liver Cancer - Pipeline by Onxeo SA, H2 2016 229 Liver Cancer - Pipeline by OPKO Health Inc, H2 2016 230 Liver Cancer - Pipeline by Oribase Pharma, H2 2016 231 Liver Cancer - Pipeline by OSE Immunotherapeutics, H2 2016 232 Liver Cancer - Pipeline by Otsuka Holdings Co Ltd, H2 2016 233 Liver Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 234 Liver Cancer - Pipeline by Peptinov SAS, H2 2016 235 Liver Cancer - Pipeline by PepVax Inc, H2 2016 236 Liver Cancer - Pipeline by Peregrine Pharmaceuticals Inc, H2 2016 237 Liver Cancer - Pipeline by Pfizer Inc, H2 2016 238 Liver Cancer - Pipeline by Pharma Mar SA, H2 2016 239 Liver Cancer - Pipeline by PharmAbcine Inc, H2 2016 240 Liver Cancer - Pipeline by PharmaEssentia Corp, H2 2016 241 Liver Cancer - Pipeline by Phosplatin Therapeutics LLC, H2 2016 242 Liver Cancer - Pipeline by ProMetic Life Sciences Inc, H2 2016 243 Liver Cancer - Pipeline by Provecs Medical GmbH, H2 2016 244 Liver Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016 245 Liver Cancer - Pipeline by RedHill Biopharma Ltd, H2 2016 246 Liver Cancer - Pipeline by Regen BioPharma Inc, H2 2016 247 Liver Cancer - Pipeline by Regulus Therapeutics Inc, H2 2016 248 Liver Cancer - Pipeline by Rigontec GmbH, H2 2016 249 Liver Cancer - Pipeline by Samumed LLC, H2 2016 250 Liver Cancer - Pipeline by Saronic Biotechnology Inc, H2 2016 251 Liver Cancer - Pipeline by Savoy Pharmaceuticals Inc, H2 2016 252 Liver Cancer - Pipeline by Shenogen Pharma Group Ltd, H2 2016 253 Liver Cancer - Pipeline by Shenzen SiBiono GeneTech Co Ltd, H2 2016 254 Liver Cancer - Pipeline by Silence Therapeutics Plc, H2 2016 255 Liver Cancer - Pipeline by Sillajen Biotherapeutics, H2 2016 256 Liver Cancer - Pipeline by Simcere Pharmaceutical Group, H2 2016 257 Liver Cancer - Pipeline by Somantix BV, H2 2016 258 Liver Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016 259 Liver Cancer - Pipeline by Synovo GmbH, H2 2016 260 Liver Cancer - Pipeline by TaiRx Inc, H2 2016 261 Liver Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2016 262 Liver Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 263 Liver Cancer - Pipeline by Targetome SA, H2 2016 264 Liver Cancer - Pipeline by TC BioPharm Ltd, H2 2016 265 Liver Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 266 Liver Cancer - Pipeline by Therapure Biopharma Inc, H2 2016 267 Liver Cancer - Pipeline by Theravectys SA, H2 2016 268 Liver Cancer - Pipeline by Threshold Pharmaceuticals Inc, H2 2016 269 Liver Cancer - Pipeline by Tiziana Life Sciences Plc, H2 2016 270 Liver Cancer - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 271 Liver Cancer - Pipeline by Transgene Biotek Ltd, H2 2016 272 Liver Cancer - Pipeline by Tumorend LLC, H2 2016 273 Liver Cancer - Pipeline by UbiVac LLC, H2 2016 274 Liver Cancer - Pipeline by VasGene Therapeutics Inc, H2 2016 275 Liver Cancer - Pipeline by Vaxon Biotech, H2 2016 276 Liver Cancer - Pipeline by Vect-Horus SAS, H2 2016 277 Liver Cancer - Pipeline by Verlyx Pharma Inc, H2 2016 278 Liver Cancer - Pipeline by VG Life Sciences Inc, H2 2016 279 Liver Cancer - Pipeline by Vicus Therapeutics LLC, H2 2016 280 Liver Cancer - Pipeline by Virttu Biologics Ltd, H2 2016 281 Assessment by Monotherapy Products, H2 2016 282 Assessment by Combination Products, H2 2016 283 Number of Products by Stage and Target, H2 2016 285 Number of Products by Stage and Mechanism of Action, H2 2016 298 Number of Products by Stage and Route of Administration, H2 2016 311 Number of Products by Stage and Molecule Type, H2 2016 313 Liver Cancer - Dormant Projects, H2 2016 1133 Liver Cancer - Dormant Projects (Contd..1), H2 2016 1134 Liver Cancer - Dormant Projects (Contd..2), H2 2016 1135 Liver Cancer - Dormant Projects (Contd..3), H2 2016 1136 Liver Cancer - Dormant Projects (Contd..4), H2 2016 1137 Liver Cancer - Dormant Projects (Contd..5), H2 2016 1138 Liver Cancer - Dormant Projects (Contd..6), H2 2016 1139 Liver Cancer - Dormant Projects (Contd..7), H2 2016 1140 Liver Cancer - Dormant Projects (Contd..8), H2 2016 1141 Liver Cancer - Dormant Projects (Contd..9), H2 2016 1142 Liver Cancer - Dormant Projects (Contd..10), H2 2016 1143 Liver Cancer - Dormant Projects (Contd..11), H2 2016 1144 Liver Cancer - Dormant Projects (Contd..12), H2 2016 1145 Liver Cancer - Dormant Projects (Contd..13), H2 2016 1146 Liver Cancer - Dormant Projects (Contd..14), H2 2016 1147 Liver Cancer - Dormant Projects (Contd..15), H2 2016 1148 Liver Cancer - Dormant Projects (Contd..16), H2 2016 1149 Liver Cancer - Dormant Projects (Contd..17), H2 2016 1150 Liver Cancer - Dormant Projects (Contd..18), H2 2016 1151 Liver Cancer - Dormant Projects (Contd..19), H2 2016 1152 Liver Cancer - Discontinued Products, H2 2016 1153 Liver Cancer - Discontinued Products (Contd..1), H2 2016 1154 Liver Cancer - Discontinued Products (Contd..2), H2 2016 1155 Liver Cancer - Discontinued Products (Contd..3), H2 2016 1156
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
